Mitogen-activated protein kinase (MEK) inhibitors
- Name
- Mitogen-activated protein kinase (MEK) inhibitors
- Accession Number
- DBCAT005740
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Cobimetinib An antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma. Trametinib A kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer. Selumetinib A MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN). Binimetinib A medication used to treat metastatic melanoma with specific mutations. - Drugs & Drug Targets